A 58-year-old male with a 40 pack-year smoking history is found to have small cell lung cancer on bronchoscopic biopsy. Which is the most common site of distant metastasis in SCLC at the time of diagnosis?

Explanation

## Sites of Distant Metastasis in SCLC **Key Point:** **Bone marrow and skeleton** (combined) represent the most common site of distant metastasis in SCLC at the time of diagnosis, occurring in approximately **20–30% of patients at presentation**. Liver is the second most common, followed by brain and adrenal glands. ### Frequency of Metastatic Sites at Diagnosis | Site | Frequency at Diagnosis | |------|------------------------| | **Bone marrow / Skeleton** | ~20–30% | | **Liver** | ~17–34% | | **Brain** | ~10–15% | | **Adrenal glands** | ~5–10% | > *Note: Figures vary across series; bone marrow + bone combined consistently rank among the highest at initial staging.* ### Why Bone Marrow is the Most Common Distant Site at Diagnosis 1. **Neuroendocrine origin with early hematogenous spread** — SCLC disseminates via the bloodstream very early; bone marrow is a highly vascular organ and a preferred site of seeding. 2. **Bone marrow biopsy positivity** — Historically, bone marrow biopsy was part of SCLC staging because marrow involvement was detected in 15–30% of patients even without radiographic bone lesions. 3. **Staging implications** — Bone/bone marrow involvement upstages patients to extensive-stage disease, which is present in ~70% at diagnosis. 4. **Clinical consequence** — Marrow infiltration can cause leukoerythroblastic anemia, thrombocytopenia, and elevated LDH. **High-Yield:** SCLC is a **systemic disease at presentation**. ~70% of patients have extensive-stage disease at diagnosis. Bone marrow involvement is detected in up to 30% at staging, making it the most common distant metastatic site overall. Brain metastases, while highly clinically significant, are less frequent at initial diagnosis (~10–15%) but increase to ~50% over the disease course. **Clinical Pearl:** **Prophylactic cranial irradiation (PCI)** is offered to SCLC patients who achieve complete response to chemotherapy, specifically to reduce the risk of brain metastases (which would otherwise occur in ~50% of long-term survivors). This underscores that brain metastases are more a cumulative risk than the dominant site at diagnosis. **Mnemonic: SCLC Metastases — "BLAH"** - **B**one marrow/skeleton (most common at diagnosis) - **L**iver - **A**drenal - **H**ead (brain — most common cumulative/during course) [cite: Harrison's Principles of Internal Medicine 21e, Ch 297; Robbins & Cotran Pathologic Basis of Disease 10e, Ch 15]